FY2025 Q3 Earnings Announcement
Committed to Growth & Shareholder Returns

from the beginning

FY2025 Q3 Earnings Announcement

Important Notice

1. Opening Remarks

Poised to Launch 3 Transformative Medicines in the Next 18 Months Setting Takeda on a New Growth Trajectory

2. Financial Highlights

FY2025 Q3 YTD: Impact of VYVANSE Generics is Tapering Off; Strong OPEX Discipline to Limit Impact to Core Operating Profit

Growth & Launch Products +6.7% at CER in Q3 YTD, with Growth Rate Improving Quarter-on-Quarter

FY2025 Q3 YTD Revenue: Narrowing the Gap Between Incremental Growth & Launch Products Revenue and VYVANSE Erosion

FY2025 Q3 YTD Core Operating Profit: Operational Efficiencies Deliver Year-on-Year Reduction in R&D and SG&A Expenses

FY2025 Q3 YTD Reported Operating Profit: Lower Restructuring Expenses More Than Offset Impairment

FY2025 Full-Year Revenue Guidance Revised Primarily due to VYVANSE; Raising Reported & Core Forecasts to Reflect FX Tailwind

Raising Core Operating Profit Forecast as Continued OPEX Discipline Fully Offsets Impact of VYVANSE, with Further Upside from FX

3. Pipeline Update

Poised to Launch 3 Transformative Medicines in the Next 18 Months Setting Takeda on a New Growth Trajectory

Accelerating Our Late-Stage Programs that have the Potential to Transform Lives and Generate Significant Value

Accelerating Our Late-Stage Programs that have the Potential to Transform Lives and Generate Significant Value

4. Closing Remarks

Bridging to The Future: Leadership Transition to Julie Kim

Q&A SESSION

• Q&A SESSION1

• Q&A SESSION2

• Q&A SESSION3

• Q&A SESSION4

• Q&A SESSION5

• Q&A SESSION6

• Q&A SESSION7

APPENDIX

GASTROENTEROLOGY (GI) ENTYVIO Momentum Continues with Expansion of ENTYVIO PEN

RARE DISEASES Sustained TAKHZYRO Growth Despite Emerging Competitive Headwinds; LIVTENCITY Strong Market Penetration in the U.S. & Rapid Geo Expansion

PLASMA-DERIVED THERAPIES Balancing Near-term Growth and Margin Improvement to Deliver

ONCOLOGY Sustainable Supply and Meet Increasing Global Patient Demand for PDTs

VACCINES QDENGA Global Demand Remains Strong

NEUROSCIENCE VYVANSE U.S. Loss of Exclusivity Impact from August 2023

Maximizing Potential of Marketed Portfolio Through LCM Expansions

Potential Key Phase 3 NME Readouts and Indication Expansions

Consolidated Development Pipeline by Phase(1)

Consolidated Development Pipeline by Phase(2)

Continuing Evidence Generation and Indication Expansion

Zasocitinib (TAK-279) Could Redefine What is Possible with an Oral Therapy, With Studies Underway Across a Broad Range of Indications

Glossary of Abbreviations

FINANCIAL APPENDIX

Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations(1)

Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations(2)

Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations(3)

FY2025 Q3 YTD Reported Results with CER % Change

FY2025 Q3 (Oct-Dec) Reported Results with CER % Change

FY2025 Q3 YTD Core Results with CER % Change

FY2025 Q3 (Oct-Dec) Core Results with CER % Change

FY2025 Q3 YTD Reconciliation from Reported to Core

FY2025 Q3 (Oct-Dec) Reconciliation from Reported to Core

FY2024 Q3 YTD Reconciliation from Reported to Core

FY2024 Q3 (Oct-Dec) Reconciliation from Reported to Core

FY2025 Q3 YTD Adjusted Free Cash Flow

FY2025 Q3 YTD Adjusted Net Debt to Adjusted EBITDA

FY2024 Adjusted Net Debt to Adjusted EBITDA

FY2025 Q3 YTD Net Profit to Adjusted EBITDA Bridge

FY2025 Q3 YTD Net Profit to Adjusted EBITDA LTM Bridge

FY2025 Q3 YTD CAPEX, Depreciation and Amortization and Impairment Losses

FY2025 Full Year Detailed Forecast

FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast

FY2025 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast

rogo